Skip to main content

Validation of an ELISA assay for Four Human IFN-Beta Therapeutics

Hero Region
Welcome to the new PBL Assay Science website!

We'd love it if you could browse around and let us know what you think -- we're a small team and appreciate the extra eyes. 

While you're browsing, if you come across any products you'd like to purchase, we're offering a month-long promotion with code: NEWSITE15

Image
Assay Kits

Optimization and Validation of an ELISA kit for the Quantitation of Four Interferon-Beta (IFN-β) Marketed Compounds in Human Serum

 

Purpose:

Interferons (IFNs) are a group of cytokines used to treat Multiple Sclerosis. Four trademarked compounds (Rebif®, Avonex®, Betaseron®, and Extavia®) were independently validated using a commercial ELISA kit over range of 5-200 pg/ml. Assay parameters were evaluated and optimized to improve the performance for the individual compounds.


 

Download PDF

Methods:

The assay quantitates Human Interferon beta (IFN-beta) in serum by sandwich enzyme linked immunosorbent assay (ELISA) and has been developed to measure low/basal levels of IFN-beta. The interferon binds to plates coated with antibody and the detection is accomplished using a biotinylated secondary antibody followed by streptavidin conjugated to horseradish peroxidase (HRP). Tetramethy-benzidine (TMB) is the substrate. Prior to preparing the standards and QCs of the fortified solutions in human serum, it was necessary to screen the matrix in order to identify the matrices with below lower limit of quantitation (BQ) levels of endogenous analyte.

 

Results:

The validation parameters of accuracy, precision, robutness, freeze-thaw stability, long-term stability, and bench-top stability were evaluated for each compound. The intra-run and inter-run )pooled) precision (%CV) and accuracy (%RE) for each validated sample concentration was ≤  20% (25% for LLOQ and ULOQ) for teh four compounds. The inter-run total error (|%CV|+|%RE|) was < 30% (<40% for LLOQ).

 

Conclusion:

Four sensitive assays for the detection of Rebif®, Avonex®, Betaseron®, and Extavia® were developed over a range of 5-200 pg/ml. The methods were reliable and robust and considered suitable for the analyses of pharmacokinetic studies in human serum.

 

HS-Human IFN-Beta ELISA validated for 4 therapeutics poster

 

Image
Female Scientist using a Microscope

Related Article

Validation Of a Highly Sensitive Immunoassay For The Quantitation Of Interferon Beta In Autoimmune Sera

Read Article